薬物誘発性疾患の臨床評価について

R S Gruchalla¹

¹Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas 75390-8859, USA. rebecca.gruchalla@email.swmed.edu

Lancet (London, England)

|November 18, 2000

まとめ

このレビューは,真のアレルギー反応と非免疫学的薬物誘発疾患を区別することによって,薬物アレルギーを報告する患者の管理を医師に助けます. 可能な限り安全な薬剤の再導入をガイドしています.

科学分野:

臨床免疫学臨床免疫学について
薬理学薬理学とは
内科内科は,内科の内科である.

背景:

患者はしばしば"薬物アレルギー"を報告し,処方箋の決定と患者のケアを複雑にします.
真のアレルギー薬剤反応と他の薬剤の副作用を区別することは,臨床的に困難です.

研究の目的:

薬物誘発性疾患の疑いのある患者の管理のための枠組みを医師に提供すること.
免疫学的に媒介されたアレルギー薬剤反応と非アレルギー薬剤有害事象を区別する.

主な方法:

薬物誘発性疾患とアレルギー反応に関する医学文献のレビュー.
病歴,身体的発見,および実験室検査を含む臨床評価ツールについての議論.
疑わしい薬物の安全な再投与に関するガイドライン.

主要な成果:

真のアレルギー薬剤反応を他の薬剤誘発状態から区別するための基準を提供します.
徹底した病歴と診断評価の重要性を強調する.
薬剤副作用の歴のある患者の管理のための戦略を提供しています.

結論:

薬剤過敏症の正確な診断は,安全な処方のために非常に重要です.
管理を改善するために,薬物誘発反応のメカニズムに関するさらなる研究が必要である.
医師は,報告された薬物アレルギーを体系的に評価することによって,患者のケアを改善することができます.

さらに関連する動画

09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

関連する概念動画

01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

関連する実験動画